{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=2&state=California", "query": { "state": "California", "city": "Fullerton", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=1&state=California&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-07T13:35:46.399Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02500706", "title": "Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Faster-acting insulin aspart", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" }, { "name": "insulin degludec", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1108, "start_date": "2016-05-04", "completion_date": "2017-08-16", "has_results": true, "last_update_posted_date": "2019-06-12", "last_synced_at": "2026-06-07T13:35:46.399Z", "location_count": 57, "location_summary": "Tucson, Arizona • Concord, California • Encino, California + 49 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02500706" }, { "nct_id": "NCT01397747", "title": "Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Neoplasms", "Digestive System Diseases", "Colonic Diseases", "Colorectal Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Exact Sciences Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "50 Years to 84 Years" }, "enrollment_count": 12776, "start_date": "2011-06", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-06-07T13:35:46.399Z", "location_count": 182, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 130 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Alhambra", "state": "California" }, { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01397747" }, { "nct_id": "NCT00657137", "title": "APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "apricoxib + lapatinib + capecitabine", "type": "DRUG" }, { "name": "placebo + lapatinib + capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tragara Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 12, "start_date": "2008-04", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-06-07T13:35:46.399Z", "location_count": 44, "location_summary": "Tucson, Arizona • Bakersfield, California • Berkeley, California + 40 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00657137" }, { "nct_id": "NCT01709864", "title": "NVA237 Versus Placebo 12-week Efficacy Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "NVA237", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 440, "start_date": "2012-11", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2015-03-04", "last_synced_at": "2026-06-07T13:35:46.399Z", "location_count": 54, "location_summary": "Homewood, Alabama • Jasper, Alabama • *See Various Dept.'s*, Arizona + 43 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "*See Various Dept.'s*", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01709864" }, { "nct_id": "NCT00524030", "title": "Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsies, Partial" ], "interventions": [ { "name": "pregabalin 600 mg/day", "type": "DRUG" }, { "name": "pregabalin 150 mg/day", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2007-09", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2021-01-20", "last_synced_at": "2026-06-07T13:35:46.399Z", "location_count": 63, "location_summary": "Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 50 more", "locations": [ { "city": "Northport", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524030" }, { "nct_id": "NCT00706914", "title": "Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Once-daily aclidinium/formoterol", "type": "DRUG" }, { "name": "Twice-daily formoterol fumarate", "type": "DRUG" }, { "name": "Placebo to formoterol fumarate", "type": "DRUG" }, { "name": "Once-daily formoterol fumarate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 156, "start_date": "2008-06-30", "completion_date": "2008-11-11", "has_results": true, "last_update_posted_date": "2017-05-15", "last_synced_at": "2026-06-07T13:35:46.399Z", "location_count": 40, "location_summary": "Tucson, Arizona • Fullerton, California • Lakewood, California + 36 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Lakewood", "state": "California" }, { "city": "Rancho Mirage", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00706914" }, { "nct_id": "NCT04064411", "title": "Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Postmenopausal Osteoporosis" ], "interventions": [ { "name": "abaloparatide", "type": "COMBINATION_PRODUCT" }, { "name": "abaloparatide solid microstructured transdermal system", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Radius Health, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "FEMALE", "summary": "50 Years to 85 Years · Female only" }, "enrollment_count": 511, "start_date": "2019-08-05", "completion_date": "2021-11-09", "has_results": true, "last_update_posted_date": "2023-02-15", "last_synced_at": "2026-06-07T13:35:46.399Z", "location_count": 77, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Glendale, Arizona + 65 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04064411" }, { "nct_id": "NCT03961698", "title": "Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "IPI-549 (eganelisib)", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Infinity Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2019-12-17", "completion_date": "2023-08-31", "has_results": false, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-06-07T13:35:46.399Z", "location_count": 24, "location_summary": "Chandler, Arizona • Tucson, Arizona • Fullerton, California + 20 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Alamitos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03961698" }, { "nct_id": "NCT02544633", "title": "Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "MGCD265", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2015-10", "completion_date": "2019-01", "has_results": true, "last_update_posted_date": "2020-03-04", "last_synced_at": "2026-06-07T13:35:46.399Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02544633" }, { "nct_id": "NCT00069121", "title": "A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin (LV)", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1886, "start_date": "2003-04-18", "completion_date": "2011-04-21", "has_results": true, "last_update_posted_date": "2020-03-06", "last_synced_at": "2026-06-07T13:35:46.399Z", "location_count": 48, "location_summary": "Mobile, Alabama • Alhambra, California • Bakersfield, California + 43 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00069121" } ] }